1
|
Diny NL, Wood MK, Won T, Talor MV, Lukban C, Bedja D, Wang N, Kalinoski H, Daoud A, Talbot CC, Leei Lin B, Čiháková D. Hypereosinophilia causes progressive cardiac pathologies in mice. iScience 2023; 26:107990. [PMID: 37829205 PMCID: PMC10565781 DOI: 10.1016/j.isci.2023.107990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 08/02/2023] [Accepted: 09/16/2023] [Indexed: 10/14/2023] Open
Abstract
Hypereosinophilic syndrome is a progressive disease with extensive eosinophilia that results in organ damage. Cardiac pathologies are the main reason for its high mortality rate. A better understanding of the mechanisms of eosinophil-mediated tissue damage would benefit therapeutic development. Here, we describe the cardiac pathologies that developed in a mouse model of hypereosinophilic syndrome. These IL-5 transgenic mice exhibited decreased left ventricular function at a young age which worsened with age. Mechanistically, we demonstrated infiltration of activated eosinophils into the heart tissue that led to an inflammatory environment. Gene expression signatures showed tissue damage as well as repair and remodeling processes. Cardiomyocytes from IL-5Tg mice exhibited significantly reduced contractility relative to wild type (WT) controls. This impairment may result from the inflammatory stress experienced by the cardiomyocytes and suggest that dysregulation of contractility and Ca2+ reuptake in cardiomyocytes contributes to cardiac dysfunction at the whole organ level in hypereosinophilic mice.
Collapse
Affiliation(s)
- Nicola Laura Diny
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Megan Kay Wood
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Taejoon Won
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Monica Vladut Talor
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Clarisse Lukban
- Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Djahida Bedja
- Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Nadan Wang
- Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Hannah Kalinoski
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | - Abdel Daoud
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - C. Conover Talbot
- Institute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Brian Leei Lin
- Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Daniela Čiháková
- W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| |
Collapse
|
2
|
Sharma D, Singh NK. The Biochemistry and Physiology of A Disintegrin and Metalloproteinases (ADAMs and ADAM-TSs) in Human Pathologies. Rev Physiol Biochem Pharmacol 2023; 184:69-120. [PMID: 35061104 DOI: 10.1007/112_2021_67] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Metalloproteinases are a group of proteinases that plays a substantial role in extracellular matrix remodeling and its molecular signaling. Among these metalloproteinases, ADAMs (a disintegrin and metalloproteinases) and ADAM-TSs (ADAMs with thrombospondin domains) have emerged as highly efficient contributors mediating proteolytic processing of various signaling molecules. ADAMs are transmembrane metalloenzymes that facilitate the extracellular domain shedding of membrane-anchored proteins, cytokines, growth factors, ligands, and their receptors and therefore modulate their biological functions. ADAM-TSs are secretory, and soluble extracellular proteinases that mediate the cleavage of non-fibrillar extracellular matrix proteins. ADAMs and ADAM-TSs possess pro-domain, metalloproteinase, disintegrin, and cysteine-rich domains in common, but ADAM-TSs have characteristic thrombospondin motifs instead of the transmembrane domain. Most ADAMs and ADAM-TSs are activated by cleavage of pro-domain via pro-protein convertases at their N-terminus, hence directing them to various signaling pathways. In this article, we are discussing not only the structure and regulation of ADAMs and ADAM-TSs, but also the importance of these metalloproteinases in various human pathophysiological conditions like cardiovascular diseases, colorectal cancer, autoinflammatory diseases (sepsis/rheumatoid arthritis), Alzheimer's disease, proliferative retinopathies, and infectious diseases. Therefore, based on the emerging role of ADAMs and ADAM-TSs in various human pathologies, as summarized in this review, these metalloproteases can be considered as critical therapeutic targets and diagnostic biomarkers.
Collapse
Affiliation(s)
- Deepti Sharma
- Department of Ophthalmology, Visual and Anatomical Sciences, Integrative Biosciences Center (IBio), Wayne State University School of Medicine, Detroit, MI, USA
| | - Nikhlesh K Singh
- Department of Ophthalmology, Visual and Anatomical Sciences, Integrative Biosciences Center (IBio), Wayne State University School of Medicine, Detroit, MI, USA.
| |
Collapse
|
3
|
Rinne P, Guillamat-Prats R, Rami M, Bindila L, Ring L, Lyytikäinen LP, Raitoharju E, Oksala N, Lehtimäki T, Weber C, van der Vorst EPC, Steffens S. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation. Arterioscler Thromb Vasc Biol 2019; 38:2562-2575. [PMID: 30354245 DOI: 10.1161/atvbaha.118.311185] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Objective- Palmitoylethanolamide is an endogenous fatty acid mediator that is synthetized from membrane phospholipids by N-acyl phosphatidylethanolamine phospholipase D. Its biological actions are primarily mediated by PPAR-α (peroxisome proliferator-activated receptors α) and the orphan receptor GPR55. Palmitoylethanolamide exerts potent anti-inflammatory actions but its physiological role and promise as a therapeutic agent in chronic arterial inflammation, such as atherosclerosis remain unexplored. Approach and Results- First, the polarization of mouse primary macrophages towards a proinflammatory phenotype was found to reduce N-acyl phosphatidylethanolamine phospholipase D expression and palmitoylethanolamide bioavailability. N-acyl phosphatidylethanolamine phospholipase D expression was progressively downregulated in the aorta of apolipoprotein E deficient (ApoE-/-) mice during atherogenesis. N-acyl phosphatidylethanolamine phospholipase D mRNA levels were also downregulated in unstable human plaques and they positively associated with smooth muscle cell markers and negatively with macrophage markers. Second, ApoE-/- mice were fed a high-fat diet for 4 or 16 weeks and treated with either vehicle or palmitoylethanolamide (3 mg/kg per day, 4 weeks) to study the effects of palmitoylethanolamide on early established and pre-established atherosclerosis. Palmitoylethanolamide treatment reduced plaque size in early atherosclerosis, whereas in pre-established atherosclerosis, palmitoylethanolamide promoted signs of plaque stability as evidenced by reduced macrophage accumulation and necrotic core size, increased collagen deposition and downregulation of M1-type macrophage markers. Mechanistically, we found that palmitoylethanolamide, by activating GPR55, increases the expression of the phagocytosis receptor MerTK (proto-oncogene tyrosine-protein kinase MER) and enhances macrophage efferocytosis, indicative of proresolving properties. Conclusions- The present study demonstrates that palmitoylethanolamide protects against atherosclerosis by promoting an anti-inflammatory and proresolving phenotype of lesional macrophages, representing a new therapeutic approach to resolve arterial inflammation.
Collapse
Affiliation(s)
- Petteri Rinne
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S).,Institute of Biomedicine and Turku Center for Disease Modeling, University of Turku, Finland (P.R.)
| | - Raquel Guillamat-Prats
- Institute of Biomedicine and Turku Center for Disease Modeling, University of Turku, Finland (P.R.)
| | - Martina Rami
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S)
| | - Laura Bindila
- Institute for Physiological Chemistry, University Medical Center, Johannes Gutenberg University Mainz, Germany (L.B.)
| | - Larisa Ring
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S)
| | - Leo-Pekka Lyytikäinen
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., E.R., N.O., T.L.)
| | - Emma Raitoharju
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., E.R., N.O., T.L.)
| | - Niku Oksala
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., E.R., N.O., T.L.).,Department of Surgery, Tampere University Hospital, Finland (N.O.)
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Finland (L.-P.L., E.R., N.O., T.L.)
| | - Christian Weber
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S).,Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, The Netherlands (C.W.).,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (C.W., S.S.)
| | - Emiel P C van der Vorst
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S)
| | - Sabine Steffens
- From the Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilians University (LMU) of Munich, Germany (P.R., R.G.-P., M.R., L.R., C.W., E.P.C.v.d.V., S.S).,German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (C.W., S.S.)
| |
Collapse
|
4
|
Schick D, Babendreyer A, Wozniak J, Awan T, Noels H, Liehn E, Bartsch JW, Vlacil AK, Grote K, Zayat R, Goetzenich A, Ludwig A, Dreymueller D. Elevated expression of the metalloproteinase ADAM8 associates with vascular diseases in mice and humans. Atherosclerosis 2019; 286:163-171. [PMID: 30910225 DOI: 10.1016/j.atherosclerosis.2019.03.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 02/17/2019] [Accepted: 03/12/2019] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND AIMS Members of the family of a disintegrin and metalloproteinases (ADAMs) and their substrates have been previously shown to modulate the inflammatory response in cardiac diseases, but studies investigating the relevance of ADAM8 are still rare. Our aim is to provide evidence for the inflammatory dysregulation of ADAM8 in vascular diseases and its association with disease severity. METHODS Western-type diet fed Apoe-/- and Ldlr-/- mice and artery ligation served as murine model for atherosclerosis and myocardial infarction, respectively. Human bypass grafts were used to study the association with coronary artery disease (CAD), with the simplified acute physiology score II (SAPS II) as a measure of postoperative organ dysfunction. Human primary vascular and blood cells were analyzed under basal and inflammatory conditions. mRNA levels were determined by RT-qPCR, ADAM8 protein levels by ELISA, immunohistochemistry or flow cytometry. RESULTS ADAM8/ADAM8 expression is associated with atherosclerosis and CAD such as myocardial infarction in both mice and humans, especially in endothelial cells and leukocytes. We observed a strong in vivo and in vitro correlation of ADAM8 with the vascular disease markers VCAM-1, ICAM-1, TNF, IL-6, and CCL-2. Serum analysis revealed a significant elevation of soluble ADAM8 serum levels correlating with soluble CXCL16 levels and SAPS II. CONCLUSIONS We demonstrate a general association of ADAM8 with cardiovascular diseases in mice and humans predominantly acting in endothelial cells and leukocytes. The correlation with postoperative organ dysfunctions in CAD patients highlights the value of further studies investigating the specific function of ADAM8 in cardiovascular diseases.
Collapse
Affiliation(s)
- Daniel Schick
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Aaron Babendreyer
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Justyna Wozniak
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Tanzeela Awan
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Heidi Noels
- Institute of Molecular Cardiovascular Research, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany
| | - Elisa Liehn
- Institute of Molecular Cardiovascular Research, University Hospital RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany; National Heart Center Singapore, Singapore, Human Genetic Laboratory, University of Medicine Craiova, Romania
| | - Jörg-W Bartsch
- Department of Neurosurgery, Philipps University Marburg, University Hospital Marburg, Baldingerstrasse, 35033, Marburg, Germany
| | - Ann-Kathrin Vlacil
- Clinic for Internal Medicine, Cardiology, Philipps University Marburg, University Hospital Marburg, Marburg, Germany
| | - Karsten Grote
- Clinic for Internal Medicine, Cardiology, Philipps University Marburg, University Hospital Marburg, Marburg, Germany
| | - Rashad Zayat
- Department of Thoracic and Cardiovascular Surgery, RWTH Aachen University Hospital, Pauwelsstr. 30, 52066, Aachen, Germany
| | - Andreas Goetzenich
- Department of Thoracic and Cardiovascular Surgery, RWTH Aachen University Hospital, Pauwelsstr. 30, 52066, Aachen, Germany
| | - Andreas Ludwig
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Wendlingweg 2, 52074, Aachen, Germany
| | - Daniela Dreymueller
- Institute of Experimental and Clinical Pharmacology and Toxicology, PZMS, ZHMB, Saarland University, UKS Bldg. 46, 66421, Homburg, Germany.
| |
Collapse
|
5
|
Rinne P, Lyytikäinen LP, Raitoharju E, Kadiri JJ, Kholova I, Kähönen M, Lehtimäki T, Oksala N. Pro-opiomelanocortin and its Processing Enzymes Associate with Plaque Stability in Human Atherosclerosis - Tampere Vascular Study. Sci Rep 2018; 8:15078. [PMID: 30305673 PMCID: PMC6180013 DOI: 10.1038/s41598-018-33523-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 09/27/2018] [Indexed: 02/08/2023] Open
Abstract
α-melanocyte-stimulating hormone (α-MSH) is processed from pro-opiomelanocortin (POMC) and mediates anti-inflammatory actions in leukocytes. α-MSH also promotes macrophage reverse cholesterol transport by inducing ATP-binding cassette transporters ABCA1 and ABCG1. Here we investigated the regulation of POMC and α-MSH expression in atherosclerosis. First, transcript levels of POMC and its processing enzymes were analyzed in human arterial plaques (n = 68) and non-atherosclerotic controls (n = 24) as well as in whole blood samples from coronary artery disease patients (n = 55) and controls (n = 45) by microarray. POMC expression was increased in femoral plaques compared to control samples as well as in unstable advanced plaques. α-MSH-producing enzyme, carboxypeptidase E, was down-regulated, whereas prolylcarboxypeptidase, an enzyme inactivating α-MSH, was up-regulated in unstable plaques compared to stable plaques, suggesting a possible reduction in intraplaque α-MSH levels. Second, immunohistochemical analyses revealed the presence of α-MSH in atherosclerotic plaques and its localization in macrophages and other cell types. Lastly, supporting the role of α-MSH in reverse cholesterol transport, POMC expression correlated with ABCA1 and ABCG1 in human plaque and whole blood samples. In conclusion, α-MSH is expressed in atherosclerotic plaques and its processing enzymes associate with plaque stability, suggesting that measures to enhance the local bioavailability of α-MSH might protect against atherosclerosis.
Collapse
Affiliation(s)
- Petteri Rinne
- Research Center for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland.,Turku Center for Disease Modeling, University of Turku, Turku, Finland
| | - Leo-Pekka Lyytikäinen
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
| | - Emma Raitoharju
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
| | - James J Kadiri
- Research Center for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland
| | - Ivana Kholova
- Department of Pathology, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
| | - Mika Kähönen
- Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
| | - Niku Oksala
- Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland. .,Department of Surgery, Tampere University Hospital, Tampere, Finland and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland and Finnish Cardiovascular Research Center-Tampere, Tampere, Finland.
| |
Collapse
|
6
|
Metalloproteinases in atherosclerosis. Eur J Pharmacol 2017; 816:93-106. [DOI: 10.1016/j.ejphar.2017.09.007] [Citation(s) in RCA: 111] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Revised: 08/31/2017] [Accepted: 09/08/2017] [Indexed: 11/20/2022]
|
7
|
Theodorou K, van der Vorst EPC, Gijbels MJ, Wolfs IMJ, Jeurissen M, Theelen TL, Sluimer JC, Wijnands E, Cleutjens JP, Li Y, Jansen Y, Weber C, Ludwig A, Bentzon JF, Bartsch JW, Biessen EAL, Donners MMPC. Whole body and hematopoietic ADAM8 deficiency does not influence advanced atherosclerotic lesion development, despite its association with human plaque progression. Sci Rep 2017; 7:11670. [PMID: 28916789 PMCID: PMC5601942 DOI: 10.1038/s41598-017-10549-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Accepted: 08/11/2017] [Indexed: 01/18/2023] Open
Abstract
Although A Disintegrin And Metalloproteinase 8 (ADAM8) is not crucial for tissue development and homeostasis, it has been implicated in various inflammatory diseases by regulating processes like immune cell recruitment and activation. ADAM8 expression has been associated with human atherosclerosis development and myocardial infarction, however a causal role of ADAM8 in atherosclerosis has not been investigated thus far. In this study, we examined the expression of ADAM8 in early and progressed human atherosclerotic lesions, in which ADAM8 was significantly upregulated in vulnerable lesions. In addition, ADAM8 expression was most prominent in the shoulder region of human atherosclerotic lesions, characterized by the abundance of foam cells. In mice, Adam8 was highly expressed in circulating neutrophils and in macrophages. Moreover, ADAM8 deficient mouse macrophages displayed reduced secretion of inflammatory mediators. Remarkably, however, neither hematopoietic nor whole-body ADAM8 deficiency in mice affected atherosclerotic lesion size. Additionally, except for an increase in granulocyte content in plaques of ADAM8 deficient mice, lesion morphology was unaffected. Taken together, whole body and hematopoietic ADAM8 does not contribute to advanced atherosclerotic plaque development, at least in female mice, although its expression might still be valuable as a diagnostic/prognostic biomarker to distinguish between stable and unstable lesions.
Collapse
Affiliation(s)
- Kosta Theodorou
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Emiel P C van der Vorst
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands.,Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Marion J Gijbels
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands.,Department of Molecular Genetics, CARIM, Maastricht University, Maastricht, The Netherlands.,Department of Medical Biochemistry, AMC, Amsterdam, Netherlands
| | - Ine M J Wolfs
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Mike Jeurissen
- Department of Molecular Genetics, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Thomas L Theelen
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Judith C Sluimer
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Erwin Wijnands
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Jack P Cleutjens
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands
| | - Yu Li
- Department of Neurosurgery, Philipps University Marburg, Marburg, Germany
| | - Yvonne Jansen
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Christian Weber
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Munich, Germany.,Department of Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands.,DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
| | - Andreas Ludwig
- Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany
| | - Jacob F Bentzon
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.,Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Jörg W Bartsch
- Department of Neurosurgery, Philipps University Marburg, Marburg, Germany
| | - Erik A L Biessen
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands.,Institute for Molecular Cardiovascular Research, RWTH Aachen, Aachen, Germany
| | - Marjo M P C Donners
- Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands.
| |
Collapse
|
8
|
Oksala N, Seppälä I, Rahikainen R, Mäkelä KM, Raitoharju E, Illig T, Klopp N, Kholova I, Laaksonen R, Karhunen P, Hytönen V, Lehtimäki T. Synergistic Expression of Histone Deacetylase 9 and Matrix Metalloproteinase 12 in M4 Macrophages in Advanced Carotid Plaques. Eur J Vasc Endovasc Surg 2017; 53:632-640. [DOI: 10.1016/j.ejvs.2017.02.014] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 02/09/2017] [Indexed: 01/16/2023]
|
9
|
Rinne P, Rami M, Nuutinen S, Santovito D, van der Vorst EPC, Guillamat-Prats R, Lyytikäinen LP, Raitoharju E, Oksala N, Ring L, Cai M, Hruby VJ, Lehtimäki T, Weber C, Steffens S. Melanocortin 1 Receptor Signaling Regulates Cholesterol Transport in Macrophages. Circulation 2017; 136:83-97. [PMID: 28450348 DOI: 10.1161/circulationaha.116.025889] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Accepted: 03/30/2017] [Indexed: 12/15/2022]
Abstract
BACKGROUND The melanocortin 1 receptor (MC1-R) is expressed by monocytes and macrophages, where it exerts anti-inflammatory actions on stimulation with its natural ligand α-melanocyte-stimulating hormone. The present study was designed to investigate the specific role of MC1-R in the context of atherosclerosis and possible regulatory pathways of MC1-R beyond anti-inflammation. METHODS Human and mouse atherosclerotic samples and primary mouse macrophages were used to study the regulatory functions of MC1-R. The impact of pharmacological MC1-R activation on atherosclerosis was assessed in apolipoprotein E-deficient mice. RESULTS Characterization of human and mouse atherosclerotic plaques revealed that MC1-R expression localizes in lesional macrophages and is significantly associated with the ATP-binding cassette transporters ABCA1 and ABCG1, which are responsible for initiating reverse cholesterol transport. Using bone marrow-derived macrophages, we observed that α-melanocyte-stimulating hormone and selective MC1-R agonists similarly promoted cholesterol efflux, which is a counterregulatory mechanism against foam cell formation. Mechanistically, MC1-R activation upregulated the levels of ABCA1 and ABCG1. These effects were accompanied by a reduction in cell surface CD36 expression and in cholesterol uptake, further protecting macrophages from excessive lipid accumulation. Conversely, macrophages deficient in functional MC1-R displayed a phenotype with impaired efflux and enhanced uptake of cholesterol. Pharmacological targeting of MC1-R in atherosclerotic apolipoprotein E-deficient mice reduced plasma cholesterol levels and aortic CD36 expression and increased plaque ABCG1 expression and signs of plaque stability. CONCLUSIONS Our findings identify a novel role for MC1-R in macrophage cholesterol transport. Activation of MC1-R confers protection against macrophage foam cell formation through a dual mechanism: It prevents cholesterol uptake while concomitantly promoting ABCA1- and ABCG1-mediated reverse cholesterol transport.
Collapse
Affiliation(s)
- Petteri Rinne
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.).
| | - Martina Rami
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Salla Nuutinen
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Donato Santovito
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Emiel P C van der Vorst
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Raquel Guillamat-Prats
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Leo-Pekka Lyytikäinen
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Emma Raitoharju
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Niku Oksala
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Larisa Ring
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Minying Cai
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Victor J Hruby
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Terho Lehtimäki
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Christian Weber
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| | - Sabine Steffens
- From Institute for Cardiovascular Prevention, Ludwig-Maximilians-University Munich, Germany (P.R., M.R., D.S., E.P.C.v.d.V., R.Q.-P., L.R., C.W., S.S.); Department of Pharmacology, Drug Development and Therapeutics, University of Turku and Turku University Hospital, Finland (P.R., S.N.); Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center, Tampere, Faculty of Medicine and Life Sciences, University of Tampere (L.-P.L., E.R., N.O., T.L.); Department of Surgery, Tampere University Hospital, Finland (N.O.); Department of Chemistry and Biochemistry, University of Arizona, Tucson (M.C., V.J.H.); and German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany (C.W., S.S.)
| |
Collapse
|
10
|
Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases. Mediators Inflamm 2017; 2017:9621724. [PMID: 28260841 PMCID: PMC5316459 DOI: 10.1155/2017/9621724] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 12/22/2016] [Indexed: 02/07/2023] Open
Abstract
Cell migration is an instrumental process involved in organ development, tissue homeostasis, and various physiological processes and also in numerous pathologies. Both basic cell migration and migration towards chemotactic stimulus consist of changes in cell polarity and cytoskeletal rearrangement, cell detachment from, invasion through, and reattachment to their neighboring cells, and numerous interactions with the extracellular matrix. The different steps of immune cell, tissue cell, or cancer cell migration are tightly coordinated in time and place by growth factors, cytokines/chemokines, adhesion molecules, and receptors for these ligands. This review describes how a disintegrin and metalloproteinases interfere with several steps of cell migration, either by proteolytic cleavage of such molecules or by functions independent of proteolytic activity.
Collapse
|
11
|
Zhang P, Shen M, Fernandez-Patron C, Kassiri Z. ADAMs family and relatives in cardiovascular physiology and pathology. J Mol Cell Cardiol 2015; 93:186-99. [PMID: 26522853 DOI: 10.1016/j.yjmcc.2015.10.031] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 10/26/2015] [Accepted: 10/28/2015] [Indexed: 12/21/2022]
Abstract
A disintegrin and metalloproteinases (ADAMs) are a family of membrane-bound proteases. ADAM-TSs (ADAMs with thrombospondin domains) are a close relative of ADAMs that are present in soluble form in the extracellular space. Dysregulated production or function of these enzymes has been associated with pathologies such as cancer, asthma, Alzheimer's and cardiovascular diseases. ADAMs contribute to angiogenesis, hypertrophy and apoptosis in a stimulus- and cell type-dependent manner. Among the ADAMs identified so far (34 in mouse, 21 in human), ADAMs 8, 9, 10, 12, 17 and 19 have been shown to be involved in cardiovascular development or cardiomyopathies; and among the 19 ADAM-TSs, ADAM-TS1, 5, 7 and 9 are important in development of the cardiovascular system, while ADAM-TS13 can contribute to vascular disorders. Meanwhile, there remain a number of ADAMs and ADAM-TSs whose function in the cardiovascular system has not been yet explored. The current knowledge about the role of ADAMs and ADAM-TSs in the cardiovascular pathologies is still quite limited. The most detailed studies have been performed in other cell types (e.g. cancer cells) and organs (nervous system) which can provide valuable insight into the potential functions of ADAMs and ADAM-TSs, their mechanism of action and therapeutic potentials in cardiomyopathies. Here, we review what is currently known about the structure and function of ADAMs and ADAM-TSs, and their roles in development, physiology and pathology of the cardiovascular system.
Collapse
Affiliation(s)
- Pu Zhang
- Department of Physiology, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
| | - Mengcheng Shen
- Department of Physiology, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
| | - Carlos Fernandez-Patron
- Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
| | - Zamaneh Kassiri
- Department of Physiology, University of Alberta, Edmonton, Alberta, Canada; Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada.
| |
Collapse
|
12
|
Oksala N, Pärssinen J, Seppälä I, Klopp N, Illig T, Laaksonen R, Levula M, Raitoharju E, Kholova I, Sioris T, Kähönen M, Lehtimäki T, Hytönen VP. Kindlin 3 (FERMT3) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds. Atherosclerosis 2015; 242:145-54. [PMID: 26188538 DOI: 10.1016/j.atherosclerosis.2015.06.058] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 05/27/2015] [Accepted: 06/29/2015] [Indexed: 12/20/2022]
Abstract
BACKGROUND Kindlins (FERMT) are cytoplasmic proteins required for integrin (ITG) activation, leukocyte transmigration, platelet aggregation and thrombosis. Characterization of kindlins and their association with atherosclerotic plaques in human(s) is lacking. METHODS AND RESULTS Exploratory microarray (MA) was first performed followed by selective quantitative validation of robustly expressed genes with qRT-PCR low-density array (LDA). In LDA, ITGA1 (1.30-fold, p = 0.041) and ITGB3 (1.37-fold, p = 0.036) were upregulated in whole blood samples of patients with coronary artery disease (CAD) compared to healthy controls. In arterial plaques, both robustly expressed transcript variants of FERMT3 (MA: 5.90- and 3.4-fold; LDA: 3.99-fold, p < 0.0001 for all) and ITGB2 (MA: 4.81- and 4.92-fold; LDA: 5.29-fold, p < 0.0001 for all) were upregulated while FERMT2 was downregulated (MA: -1.61-fold; LDA: -2.88-fold, p < 0.0001 for both). The other integrins (ITGA1, ITGAV, ITGB3, ITGB5) were downregulated. All these results were replicated in at least one arterial bed. The latter FERMT3 transcript variant associated with unstable plaques (p = 0.0004). FERMT3 correlated with M2 macrophage markers and in hierarchical cluster analysis clustered with inflammatory and macrophage markers, while FERMT2 correlated with SMC-rich plaque markers and clustered with SMC markers. In confocal immunofluorescence analysis, FERMT3 protein colocalized with abundant CD68-positive cells of monocytic origin in the atherosclerotic plaques, while co-localization of FERMT3 with HHF35 indicative of smooth muscle cells was low. CONCLUSIONS Kindlin-3 (FERMT3) is upregulated in atherosclerotic, especially unstable plaques, mainly in cells of monocytic origin and of M2 type. Simultaneous upregulation of ITGB2 suggests a synergistic effect on leukocyte adherence and transmigration into the vessel wall.
Collapse
Affiliation(s)
- Niku Oksala
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; School of Medicine, University of Tampere, Finland; Division of Vascular Surgery, Department of Surgery, Tampere University Hospital, Finland.
| | - Jenita Pärssinen
- BioMediTech, University of Tampere, Tampere, Finland and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Ilkka Seppälä
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Norman Klopp
- Research Unit of Molecular Epidemiology, Helmholtz Zentrum, German Research Center for Environmental Health, Munich, Germany; Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
| | - Thomas Illig
- Research Unit of Molecular Epidemiology, Helmholtz Zentrum, German Research Center for Environmental Health, Munich, Germany; Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
| | - Reijo Laaksonen
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; School of Medicine, University of Tampere, Finland
| | - Mari Levula
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Emma Raitoharju
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Ivana Kholova
- Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - Thanos Sioris
- Heart Center, Tampere University Hospital, Tampere, Finland
| | - Mika Kähönen
- School of Medicine, University of Tampere, Finland; Division of Vascular Surgery, Department of Surgery, Tampere University Hospital, Finland; Department of Clinical Physiology, Tampere University Hospital, Tampere, Finland
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland; School of Medicine, University of Tampere, Finland
| | - Vesa P Hytönen
- BioMediTech, University of Tampere, Tampere, Finland and Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| |
Collapse
|
13
|
Kirsten H, Al-Hasani H, Holdt L, Gross A, Beutner F, Krohn K, Horn K, Ahnert P, Burkhardt R, Reiche K, Hackermüller J, Löffler M, Teupser D, Thiery J, Scholz M. Dissecting the genetics of the human transcriptome identifies novel trait-related trans-eQTLs and corroborates the regulatory relevance of non-protein coding loci†. Hum Mol Genet 2015; 24:4746-63. [PMID: 26019233 PMCID: PMC4512630 DOI: 10.1093/hmg/ddv194] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 05/21/2015] [Indexed: 12/24/2022] Open
Abstract
Genetics of gene expression (eQTLs or expression QTLs) has proved an indispensable tool for understanding biological pathways and pathomechanisms of trait-associated SNPs. However, power of most genome-wide eQTL studies is still limited. We performed a large eQTL study in peripheral blood mononuclear cells of 2112 individuals increasing the power to detect trans-effects genome-wide. Going beyond univariate SNP-transcript associations, we analyse relations of eQTLs to biological pathways, polygenetic effects of expression regulation, trans-clusters and enrichment of co-localized functional elements. We found eQTLs for about 85% of analysed genes, and 18% of genes were trans-regulated. Local eSNPs were enriched up to a distance of 5 Mb to the transcript challenging typically implemented ranges of cis-regulations. Pathway enrichment within regulated genes of GWAS-related eSNPs supported functional relevance of identified eQTLs. We demonstrate that nearest genes of GWAS-SNPs might frequently be misleading functional candidates. We identified novel trans-clusters of potential functional relevance for GWAS-SNPs of several phenotypes including obesity-related traits, HDL-cholesterol levels and haematological phenotypes. We used chromatin immunoprecipitation data for demonstrating biological effects. Yet, we show for strongly heritable transcripts that still little trans-chromosomal heritability is explained by all identified trans-eSNPs; however, our data suggest that most cis-heritability of these transcripts seems explained. Dissection of co-localized functional elements indicated a prominent role of SNPs in loci of pseudogenes and non-coding RNAs for the regulation of coding genes. In summary, our study substantially increases the catalogue of human eQTLs and improves our understanding of the complex genetic regulation of gene expression, pathways and disease-related processes.
Collapse
Affiliation(s)
- Holger Kirsten
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases, Cognitive Genetics, Department of Cell Therapy
| | - Hoor Al-Hasani
- Department for Computer Science, Analysis Strategies Group, Department of Diagnostics, Young Investigators Group Bioinformatics and Transcriptomics, Department Proteomics, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany and
| | - Lesca Holdt
- Institute of Laboratory Medicine, Ludwig-Maximilians-University, Munich, Germany
| | - Arnd Gross
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases
| | - Frank Beutner
- LIFE - Leipzig Research Center for Civilization Diseases, Department of Internal Medicine/Cardiology, Heart Center
| | - Knut Krohn
- Interdisciplinary Center for Clinical Research, Faculty of Medicine and
| | - Katrin Horn
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases
| | - Peter Ahnert
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases
| | - Ralph Burkhardt
- LIFE - Leipzig Research Center for Civilization Diseases, Institute of Laboratory Medicine, University of Leipzig, Leipzig, Germany
| | - Kristin Reiche
- Department for Computer Science, RNomics Group, Department of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology- IZI, Leipzig, Germany, Young Investigators Group Bioinformatics and Transcriptomics, Department Proteomics, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany and
| | - Jörg Hackermüller
- Department for Computer Science, RNomics Group, Department of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology- IZI, Leipzig, Germany, Young Investigators Group Bioinformatics and Transcriptomics, Department Proteomics, Helmholtz Centre for Environmental Research - UFZ, Leipzig, Germany and
| | - Markus Löffler
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases
| | - Daniel Teupser
- Institute of Laboratory Medicine, Ludwig-Maximilians-University, Munich, Germany
| | - Joachim Thiery
- LIFE - Leipzig Research Center for Civilization Diseases, Institute of Laboratory Medicine, University of Leipzig, Leipzig, Germany
| | - Markus Scholz
- Institute for Medical Informatics, Statistics and Epidemiology, LIFE - Leipzig Research Center for Civilization Diseases,
| |
Collapse
|
14
|
Upstream Transcription Factor 1 (USF1) allelic variants regulate lipoprotein metabolism in women and USF1 expression in atherosclerotic plaque. Sci Rep 2014; 4:4650. [PMID: 24722012 PMCID: PMC3983598 DOI: 10.1038/srep04650] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2014] [Accepted: 03/26/2014] [Indexed: 11/25/2022] Open
Abstract
Upstream transcription factor 1 (USF1) allelic variants significantly influence future risk of cardiovascular disease and overall mortality in females. We investigated sex-specific effects of USF1 gene allelic variants on serum indices of lipoprotein metabolism, early markers of asymptomatic atherosclerosis and their changes during six years of follow-up. In addition, we investigated the cis-regulatory role of these USF1 variants in artery wall tissues in Caucasians. In the Cardiovascular Risk in Young Finns Study, 1,608 participants (56% women, aged 31.9 ± 4.9) with lipids and cIMT data were included. For functional study, whole genome mRNA expression profiling was performed in 91 histologically classified atherosclerotic samples. In females, serum total, LDL cholesterol and apoB levels increased gradually according to USF1 rs2516839 genotypes TT < CT < CC and rs1556259 AA < AG < GG as well as according to USF1 H3 (GCCCGG) copy number 0 < 1 < 2. Furthermore, the carriers of minor alleles of rs2516839 (C) and rs1556259 (G) of USF1 gene had decreased USF1 expression in atherosclerotic plaques (P = 0.028 and 0.08, respectively) as compared to non-carriers. The genetic variation in USF1 influence USF1 transcript expression in advanced atherosclerosis and regulates levels and metabolism of circulating apoB and apoB-containing lipoprotein particles in sex-dependent manner, but is not a major determinant of early markers of atherosclerosis.
Collapse
|
15
|
Oksala N, Pärssinen J, Seppälä I, Raitoharju E, Ivana K, Hernesniemi J, Lyytikäinen LP, Levula M, Mäkelä KM, Sioris T, Kähönen M, Laaksonen R, Hytönen V, Lehtimäki T. Association of Neuroimmune Guidance Cue Netrin-1 and Its Chemorepulsive Receptor UNC5B With Atherosclerotic Plaque Expression Signatures and Stability in Human(s). ACTA ACUST UNITED AC 2013; 6:579-87. [DOI: 10.1161/circgenetics.113.000141] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Background—
Macrophage (MΦ) infiltration and smooth muscle cell (SMC) proliferation are hallmarks of atherosclerosis and unstable plaques. Neuroimmune guidance cue 1 (netrin-1 [NTN1]) plays a critical role controlling MΦ trafficking and SMC activation. Characterization of expression of NTN1 and its receptors and their association with plaque stability in human(s) is lacking.
Methods and Results—
The expression of NTN1 and its receptors did not differ in either whole blood or circulating monocytes from patients with coronary artery disease (n=55) compared with healthy controls (n=45). However, NTN1 was downregulated (−2.9-fold;
P
<0.0001) and UNC5B upregulated (2.2-fold;
P
<0.0001) in atherosclerotic plaques (n=68), whereas there were no differences in other NTN1 receptors compared with histologically normal controls (n=28). Increased UNC5B expression is associated with histologically more stable plaques (
P
=0.011). NTN1 expression correlated positively with SMC markers and signatures and negatively with inflammatory markers and M1 and especially M2 signatures in the atherosclerotic plaques. UNC5B clustering correlated positively with inflammatory and MΦ markers. NTN1 protein colocalized with CD68-positive cells of monocytic origin and muscle-actin-specific-antibody (HHF3)-positive cells indicative of SMCs in the plaques and only with SMCs in the control samples. NTN1 protein was highly expressed in the intimal layer of the control vessels.
Conclusions—
Present findings provide support for the hypothesis that dysregulation of expression of NTN1 in SMCs and its chemorepulsive receptor UNC5B in macrophages are involved in the development of atherosclerosis and unstable plaques.
Collapse
Affiliation(s)
- Niku Oksala
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Jenita Pärssinen
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Ilkka Seppälä
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Emma Raitoharju
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Kholova Ivana
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Jussi Hernesniemi
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Leo-Pekka Lyytikäinen
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Mari Levula
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Kari-Matti Mäkelä
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Thanos Sioris
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Mika Kähönen
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Reijo Laaksonen
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Vesa Hytönen
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| | - Terho Lehtimäki
- From the Department of Clinical Chemistry (N.O., I.S., E.R., J.H., L.-P.L., M.L., K.-M.M., R.L., T.L.), Institute of Biomedical Technology and BioMediTech (J.P., V.H.), and Department of Pathology (K.I.), Fimlab Laboratories, University of Tampere and Tampere University Hospital, Tampere, Finland; and Division of Vascular Surgery, Department of Surgery (N.O.) and Heart Center (T.S.), and Department of Clinical Physiology (M.K.), Tampere University Hospital, University of Tampere, Tampere, Finland
| |
Collapse
|
16
|
Hall T, Shieh HS, Day JE, Caspers N, Chrencik JE, Williams JM, Pegg LE, Pauley AM, Moon AF, Krahn JM, Fischer DH, Kiefer JR, Tomasselli AG, Zack MD. Structure of human ADAM-8 catalytic domain complexed with batimastat. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012; 68:616-21. [PMID: 22684055 PMCID: PMC3370895 DOI: 10.1107/s1744309112015618] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2012] [Accepted: 04/10/2012] [Indexed: 11/11/2022]
Abstract
The role of ADAM-8 in cancer and inflammatory diseases such as allergy, arthritis and asthma makes it an attractive target for drug development. Therefore, the catalytic domain of human ADAM-8 was expressed, purified and crystallized in complex with a hydroxamic acid inhibitor, batimastat. The crystal structure of the enzyme-inhibitor complex was refined to 2.1 Å resolution. ADAM-8 has an overall fold similar to those of other ADAM members, including a central five-stranded β-sheet and a catalytic Zn(2+) ion. However, unique differences within the S1' binding loop of ADAM-8 are observed which might be exploited to confer specificity and selectivity to ADAM-8 competitive inhibitors for the treatment of diseases involving this enzyme.
Collapse
Affiliation(s)
- Troii Hall
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Huey-Sheng Shieh
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Jacqueline E. Day
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Nicole Caspers
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Jill E. Chrencik
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | | | - Lyle E. Pegg
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Adele M. Pauley
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - Andrea F. Moon
- Laboratory of Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T. W. Alexander Drive, Building 101/MD F3-09, Research Triangle Park, NC 27709, USA
| | - Joseph M. Krahn
- Laboratory of Structural Biology, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T. W. Alexander Drive, Building 101/MD F3-09, Research Triangle Park, NC 27709, USA
| | - David H. Fischer
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | - James R. Kiefer
- Pfizer Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017, USA
| | | | - Marc D. Zack
- Dow AgroSciences LLC, 9330 Zionsville Road, Indianapolis, IN 46268, USA
| |
Collapse
|
17
|
van der Vorst EPC, Keijbeck AA, de Winther MPJ, Donners MMPC. A disintegrin and metalloproteases: molecular scissors in angiogenesis, inflammation and atherosclerosis. Atherosclerosis 2012; 224:302-8. [PMID: 22698791 DOI: 10.1016/j.atherosclerosis.2012.04.023] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Revised: 04/25/2012] [Accepted: 04/26/2012] [Indexed: 01/19/2023]
Abstract
A disintegrin and metalloproteases (ADAMs) are enzymes that cleave (shed) the extracellular domains of various cell surface molecules, e.g. adhesion molecules, cytokine/chemokine and growth factor receptors, thereby releasing soluble molecules that can exert agonistic or antagonistic functions or serve as biomarkers. By functioning as such molecular scissors, ADAM proteases have been implicated in various diseases, e.g. cancer, and their role in cardiovascular diseases is now emerging. This review will focus on the role of ADAM proteases in molecular mechanisms of angiogenesis and inflammation in relation to atherosclerosis. Besides a concise overview of the current state and recent advances of this research area, we will discuss key questions about redundancy, specificity and regulation of ADAM proteases and emphasize the importance of confirmation of in vitro findings in in vivo models.
Collapse
Affiliation(s)
- Emiel P C van der Vorst
- Department of Molecular Genetics, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
| | | | | | | |
Collapse
|
18
|
Vuohelainen V, Raitoharju E, Levula M, Lehtimaki T, Pelto-Huikko M, Honkanen T, Huovila A, Paavonen T, Tarkka M, Mennander A. Myocardial infarction induces early increased remote ADAM8 expression of rat hearts after cardiac arrest. Scand J Clin Lab Invest 2011; 71:553-62. [PMID: 21728900 DOI: 10.3109/00365513.2011.591424] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND A disintegrin and metalloproteinase-8 (ADAM8) is a potential surrogate of inflammation which has recently been associated with myocardial infarction. We evaluated in a rat cardiac transplantation model whether ischemia-reperfusion injury alone (IRI) or with early regional myocardial infarction (MI) would suffice to induce inflammatory myocardial remodeling and ADAM8 expression. MATERIAL AND METHODS Isogenic heterotopic cardiac transplantation after cardiac arrest was performed to 48 Fischer 344 rats to induce ischemia-reperfusion injury (IRI), of which 27 rats also underwent ligation of the left anterior coronary artery (LAD) of the heart to yield MI. Histology was performed at 0.5, 24 and 48 h after transplantation. ADAM8 was evaluated by qRT-PCR after graft harvesting. RESULTS After 0.5 and 48 h respectively, edematous intramyocardial artery nuclei and periadventitial inflammation were more prominent in MI after transplantation, as compared with IRI alone and Controls (57.0 vs 40.0 and 5.0; 1.9 vs 1.1 and 0.9, point score units, p < 0.05, respectively). The expression of ADAM-8 was increased in MI as compared with Controls (1.9 vs 1.0, 1.9 fold increase) at 48 h. In grafts with MI, ADAM8 was localized using immunohistochemistry to the vicinity of the area corresponding to the developing infarction as well as in intramyocardial arteries remote to the infarction area. CONCLUSIONS Remote histopathological changes of ischemic cardiac grafts are associated with increased expression of ADAM8 thus emphasizing a global myocardial impact of MI.
Collapse
Affiliation(s)
- Vilma Vuohelainen
- Heart Center, Cardiac Research, Tampere University Hospital, Tampere, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Hall T, Pegg LE, Pauley AM, Fischer HD, Tomasselli AG, Zack MD. ADAM8 substrate specificity: influence of pH on pre-processing and proteoglycan degradation. Arch Biochem Biophys 2009; 491:106-11. [PMID: 19766586 DOI: 10.1016/j.abb.2009.09.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2009] [Revised: 09/09/2009] [Accepted: 09/12/2009] [Indexed: 11/25/2022]
Abstract
A disintegrin and metalloprotease-8 (ADAM8) is thought to play a role in cancer and inflammatory diseases such as allergy, arthritis, and asthma. Despite the implication of ADAM8 in these diseases, the functional role of ADAM8 catalytic activity remains unclear. In this report, we demonstrate that an early critical autolytic event, we have termed pre-processing, is accelerated at acidic pH (pH 5.5) while autolytic activation is abrogated under the same conditions. Likewise, we found that pre-processing is hindered and autolytic activation is facilitated in neutral pH conditions, and thus demonstrates a pH-dependent shift in substrate selectivity. This finding is further supported by two peptide substrates corresponding to the pre-processing and C-terminal scissile bonds that were preferentially cleaved at acidic and neutral pH, respectively. Lastly, we found fibronectin cleavage to be attenuated at pH 5.5, while two novel substrates, brevican, and vitronectin, were readily cleaved in neutral or acidic conditions.
Collapse
Affiliation(s)
- Troii Hall
- Pfizer Inc., Global Research and Development, St. Louis Laboratories, St. Louis, MO 63017-1732, USA
| | | | | | | | | | | |
Collapse
|